<bill session="107" type="h" number="1862" updated="2013-07-14T18:57:40-04:00">
  <state datetime="2001-05-16">REFERRED</state>
  <status>
    <introduced datetime="2001-05-16"/>
  </status>
  <introduced datetime="2001-05-16"/>
  <titles>
    <title as="introduced" type="short">Greater Access to Affordable Pharmaceuticals Act of 2001</title>
    <title as="introduced" type="official">To amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals.</title>
  </titles>
  <sponsor id="400050"/>
  <cosponsors>
    <cosponsor id="400007" joined="2001-05-16"/>
    <cosponsor id="400011" joined="2002-04-10"/>
    <cosponsor id="400525" joined="2001-05-16"/>
    <cosponsor id="400013" joined="2002-09-24"/>
    <cosponsor id="400526" joined="2001-06-12"/>
    <cosponsor id="400553" joined="2001-06-26"/>
    <cosponsor id="400023" joined="2001-10-02"/>
    <cosponsor id="400026" joined="2002-06-20"/>
    <cosponsor id="400518" joined="2001-06-28"/>
    <cosponsor id="400527" joined="2001-06-07"/>
    <cosponsor id="400047" joined="2001-06-12"/>
    <cosponsor id="400067" joined="2002-02-13"/>
    <cosponsor id="400073" joined="2002-05-22"/>
    <cosponsor id="400087" joined="2002-04-10"/>
    <cosponsor id="400100" joined="2001-05-25"/>
    <cosponsor id="400103" joined="2002-04-10"/>
    <cosponsor id="400106" joined="2001-06-26"/>
    <cosponsor id="400116" joined="2002-05-22"/>
    <cosponsor id="400121" joined="2001-05-16"/>
    <cosponsor id="400133" joined="2001-06-12"/>
    <cosponsor id="400140" joined="2001-05-16"/>
    <cosponsor id="400143" joined="2001-06-12"/>
    <cosponsor id="400178" joined="2001-07-17"/>
    <cosponsor id="400195" joined="2002-07-09"/>
    <cosponsor id="400210" joined="2002-09-24"/>
    <cosponsor id="400211" joined="2001-05-16"/>
    <cosponsor id="400215" joined="2002-07-22"/>
    <cosponsor id="400216" joined="2001-07-17"/>
    <cosponsor id="400218" joined="2002-06-20"/>
    <cosponsor id="400221" joined="2002-07-09"/>
    <cosponsor id="400227" joined="2001-06-12"/>
    <cosponsor id="400230" joined="2001-06-07"/>
    <cosponsor id="400235" joined="2001-06-07"/>
    <cosponsor id="400237" joined="2002-09-24"/>
    <cosponsor id="400246" joined="2001-10-02"/>
    <cosponsor id="400251" joined="2002-09-24"/>
    <cosponsor id="400545" joined="2001-10-02"/>
    <cosponsor id="400257" joined="2001-05-25"/>
    <cosponsor id="400263" joined="2001-06-07"/>
    <cosponsor id="400513" joined="2001-07-11"/>
    <cosponsor id="400268" joined="2002-09-26"/>
    <cosponsor id="400289" joined="2002-02-13"/>
    <cosponsor id="400295" joined="2002-05-22"/>
    <cosponsor id="400301" joined="2002-04-10"/>
    <cosponsor id="400308" joined="2001-05-16"/>
    <cosponsor id="400321" joined="2001-06-07"/>
    <cosponsor id="400331" joined="2001-06-26"/>
    <cosponsor id="400528" joined="2002-02-13"/>
    <cosponsor id="400345" joined="2002-07-22"/>
    <cosponsor id="400347" joined="2001-07-11"/>
    <cosponsor id="400357" joined="2001-05-16"/>
    <cosponsor id="400361" joined="2002-09-24"/>
    <cosponsor id="400530" joined="2001-05-16"/>
    <cosponsor id="400378" joined="2001-06-26"/>
    <cosponsor id="400390" joined="2001-11-06"/>
    <cosponsor id="400391" joined="2001-05-16"/>
    <cosponsor id="400546" joined="2002-06-04"/>
    <cosponsor id="400509" joined="2001-05-16"/>
    <cosponsor id="400407" joined="2001-07-11"/>
    <cosponsor id="400413" joined="2002-05-22"/>
    <cosponsor id="400516" joined="2002-09-11"/>
    <cosponsor id="400436" joined="2002-06-20"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2001-05-16">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2001-06-01">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
    <action datetime="2002-05-07">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR H2110"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills>
    <bill relation="rule" session="107" type="hr" number="517"/>
    <bill relation="identical" session="107" type="s" number="812"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Actions and defenses"/>
    <term name="Administrative procedure"/>
    <term name="Administrative remedies"/>
    <term name="Commerce"/>
    <term name="Competition"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Consent decrees"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Generic drugs"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Governmental investigations"/>
    <term name="Intellectual property"/>
    <term name="Judicial opinions"/>
    <term name="Law"/>
    <term name="Patents"/>
    <term name="Pharmaceutical research"/>
    <term name="Prescription pricing"/>
    <term name="Restrictive trade practices"/>
    <term name="Right of petition"/>
    <term name="Science, technology, communications"/>
  </subjects>
  <amendments/>
  <summary>5/16/2001--Introduced.
Greater Access to Affordable Pharmaceuticals Act of 2001 - Amends the Federal Food, Drug, and Cosmetic Act to provide for an accelerated date of approval for a generic drug application.Allows a drug to be considered a bioequivalent to a listed drug if the effects of such drug and the listed drug do not show a significant difference based on certain tests or studies.Sets forth requirements concerning the filing of a citizen petition review.Revises provisions concerning: (1) abbreviated new drug applications and new drug applications with respect to the time required for approval and the certification that a patent is invalid or will not be infringed; and (2) filing an application.Requires a report concerning the extent to which this Act has: (1) has enabled products to come to market in a fair and expeditious manner, consistent with the rights of patent owners under intellectual property law; and (2) has promoted lower prices of drugs and greater access to drugs through price competition..</summary>
</bill>
